ZA200102731B

ZA200102731B - Compositions of and process for producing isotretinoin having low particle size.

Info

Publication number: ZA200102731B
Application number: ZA200102731A
Authority: ZA
Inventors: Hashim A Ahmed; Martin Howard Infeld; Navnit Hargovindas Shah
Original assignee: Hoffman Laroche Ag F
Priority date: 1998-10-30
Filing date: 2001-04-03
Publication date: 2002-07-03
Also published as: BR9914932A; JP2002528492A; WO2000025772A1; AU1044400A; PE20001227A1; CN1324235A; EP1131068A1; AR020999A1; KR20010073226A; NO20012014L; NO20012014D0; TR200101156T2; CA2347098A1

Description

i 6 WO00125772 PCT/EP99/08208

COMPOSITIONS OF AND PROCESS FOR PRODUCING ISOTRETINOIN

HAVING LOW PARTICLE SIZE

The invention relates to a new process for making a micronized isotretinoin composition, specifically to a process for producing low particle size isotretinoin, to compositions comprising isotretinoin produced by this process, and to isotretinoin compositions having reduced food effect on bioavailabitily.

Isotretinoin is used for the treatment of severe, recalcitrant cystic acne. The presently marketed product ROACCUTANED® is a suspension of isotretinoin filled in soft gelatin capsules. The mean particle size of the isotretinoin in the suspension is about 90-100 pm (micrometers). This particle size is produced by subjecting a suspension of isotretinoin in an oil (preferably soybean oil) to high shear homogenization for a time sufficient to reduce the mean particle size of the isotretinoin to 90-100 pm. However, the bioavailability of the isotretinoin in

ACCUTANE is only about 20%. Therefore, it was desired to reduce the particle size \ 15 of isotretinoin in the suspension to improve bioavailability and also potentially reduce intra subject variability.

The reduction of isotretinoin particle size is not without problems. The particle size reduction using prior art methods, such as a hammer mill, a ball mill or an air attrition (fluid energy) mill result in a significant loss in potency of the isotretinoin.

Isotretinoin is very sensitive to oxidation, and prolonged exposure to the atmosphere during milling causes substantial loss in potency. Moreover, ball milling results in contamination of the drug with the grinding media. Therefore, these approaches are not suitable for an isotretinoin commercial application.

It has been found that isotretinoin powder can be micronized with negligible loss of potency by suspending the isotretinoin in an oily or other pharmaceutically acceptable vehicle, and then subjecting the suspension to impact, shear and cavitation forces produced by high shear homogenization, liquid jet micronization (as defined below) or wet milling; efficient particle size reduction occurs with

CONFIRMATION COPY negligible loss in its potency. Thus one of the embodiments of the invention is an improved process for making a micronized isotretinoin composition. It was also } surprisingly found that the isotretinoin composition thus produced was more storage stable with respect to isotretinoin potency than a similar composition in which the isotretinoin was first micronized and then suspended in the oil.

Therefore, in accordance with the present invention, isotretinoin suspended in the oily or other pharmaceutically acceptable vehicle may be micronized by a number of techniques without a negative effect on the potency of the isotretinoin, and the suspension and soft gelatin capsules produced from this suspension exhibit excellent uniformity, bioavailability and stability of potency. Thus, further embodiments of the invention are 1) a composition comprising a suspension of isotretinoin in an oily or other pharmaceutically acceptable vehicle produced by micronizing the isotretinoin in the vehicle, and 2) a unit dosage for for enteral administration containing the composition.

The subject invention provides a pharmaceutical composition in unit dosage form.

This composition comprises a suspension containing from about 7.5 mg to about 22.5 mg of isotretinoin having a mean particle size between 5 pm and 30 um, from 10% by weight to 18% by weight of wax, preferably 18% wax, and an oil. Other useful additives in the suspension include disodium edetate and butylated . hydroxyanisole. The suspension typically contains a wax mixture comprising beeswax, hydrogenated soybean oil flakes, and hydrogenated vegetable oil, and an ] oil, such as soybean oil. A preferred isotretinoin has a mean particle size between 5 um and 26 pm.

As used herein, the term “liquid jet micronizer” refers to devices which utilize the micronization technology disclosed in U.S. Patent Nos. 4,533,254 and 4,908,154 the disclosures of which are hereby incorporated by reference.

The term “oily or other pharmaceutically acceptable vehicle” as used in the subject application means any liquid that is (i) pharmaceutically acceptable for oral administration into humans, (ii) of suitable fluidity and viscosity for suspending the isotretinoin while the vehicle and isotretinoin are subjected to mechanical means that produce shear, impact, cavitation or attrition so as to reduce the mean particle size of the isotretinoin to a particle size in the range of from about 5 um to io . WO 0025772 PCT/EP99/08208 : ony Cd 3 ~ about 30 pm, and (iii) compatible with maintaining the integrity of the capsule that is to contain the suspension. A preferred class of vehicle is an oily vehicle. An oily vehicle may be any conventional vegetable or synthetic oil pharmaceutically acceptable for oral administration. Preferred oily vehicles include soybean oil, peanut oil, olive oil, mono-, di- and triglycerides of Cq-C,3 fatty acids, Cs-Cis fatty acids, polyethylene glycol, polyglycolized glycerides, glycerol, propylene glycol, mono-, di- and triesters of propylene glycol and polyethylene glycols. Mixtures of two or more oily vehicles useful in accordance with the present invention may also be used. An especially preferred oily vehicle is soybean oil.

Thus, the present invention is directed to a process for the manufacture of a micronized isotretinoin composition comprised of micronized isotretinoin dispersed in an oily or other pharmaceutically acceptable vehicle in which the micronized isotretinoin in said composition has a mean particle size in the range from about 5 pm to about 30 pm preferably from about 5 pm to about 26 pm, most 15° preferably from about 5 um to about 20 pm. The process comprises subjecting a © suspension of isotretinoin in the oily or other pharmaceutically acceptable vehicle to mechanical means which produce shear, impact, cavitation or attrition whereby the mean particle size of the isotretinoin is reduced so as to produce the micronized isotretinoin composition. The starting isotretinoin, as distinguished from the micronized isotretinoin, generally has a mean particle size in the range from 100 pum to about 300 pm. The process of the invention may be carried out in more than one step using different mechanical means for each step, e.g., high shear homogenization followed by liquid jet micronization.

In a preferred embodiment, isotretinoin is suspended in the oily or other pharmaceutically acceptable vehicle and processed through a high shear homogenizer followed by a liquid jet micronizer. Particle size reduction using the high sheat homogenizer is preferably carried out until the mean particle size of the isotretinoin in the suspension is in the range of 50-65 pm. In these two steps, the mean particle size of the isotretinoin is reduced from 100-300 pm to about 5- 30 um preferably to about 5-26 pm most preferably to about 5-20 um. The resulting particle size is also very uniformly reproduced with negligible loss in isotretinoin potency.

The especially preferred liquid jet micronizers are those manufactured by

Microfluidics Corp., Newton, MA, under the name MICROFLUIDIZER®. A . recycling of the isotretinoin dispersion in the liquid jet micronizer as described in the US Patents Nos. 4 533 254 and 4 908 154 may be done, if desired, to achieve the desired size of the dispersed isotretinoin particles and/or to make them of more uniform size. In the liquid jet micronizer, the use of a larger interaction chamber in sequence with a smaller interaction chamber is preferably used.

In the preferred embodiment of the invention, the suspension from the high shear homogenizer is passed through a liquid jet micronizer at any conventional temperature at which the desired micronization may be achieved. Temperatures in the range of 15°-50°C are preferred. It is especially preferred to carry out the liquid jet micronization at room temperature. The liquid jet micronizer is preferably operated at 5,000 to 40,000 psi pressure especially at 10,000 to 30,000 psi, most preferably at 12,000 to 18,000 psi, to achieve the final particle size reduction. In a typical case, the homogenized suspension is processed twice through the liquid jet micronizer at a pressure of about 12,000 psi.

In alternative embodiments, the particle size reduction may be completed using only the high shear homogenizer for a sufficient time to yield the mean particle size of 5-30 um especially of 5-26 um, most preferably of 5-20 um, or be performed ’ using wet milling alone or liquid jet micronization alone. Examples of high shear homogenizers are impeller-type high shear mixers which may be obtained from

Arde Barinco (New Jersey; e.g., Model CJ4C 16#), Koruma (Germany; e.g., Model

DISHO-V), GEI Krieger (Switzerland; e.g., Model BL) and Silverson (England; e.g.,

Model L4 RT). Examples of wet mills are the Dispermat SL (VMA-Getzmann

GMBH, Germany) and the Dyno-Mill Type KDL (Willy Bachofen AG

Maschinenfabrik, Switzerland).

In a preferred embodiment of the invention, the process of the invention is carried out on a dispersion of isotretinoin in the oily or other pharmaceutically acceptable vehicle, preferably in an oily vehicule, alone or with just a conventional antioxidant, without the further excipients that might be utilized in the final formulation for filling gelatin capsules. Such a “stock dispersion” of micronized isotretinoin in the oily or other pharmaceutically acceptable vehicle is preferably used to prepare the final formulation for filling gelatin capsules. In preparation for

. & on WO 0025772 PCT/EP99/08208 oy “3 5 micronization, powdered isotretinoin may be mixed with the oily or other pharmaceutically acceptable vehicle by any conventional means. The isotretinoin in the vehicle is micronized, and then the resulting stock dispersion may be mixed with excipients to form the final formulation used for filling gelatin capsules. An example of a conventional antioxidant that might be incorporated in a stock dispersion is butylated hydroxyanisole.

One general procedure for preparing the stock dispersion is to warm the oily or other pharmaceutically acceptable vehicle to facilitate mixing (about 70°C is suitable), and dissolve the antioxidant in the vehicle using a propeller mixer or equivalent. The solution of the antioxidant in vehicle is cooled to about 35°-40° C.

Isotretinoin, which is preferably stored at -20 °C in a sealed container, is brought to room temperature and the container is opened and the drug is stirred into the solution of the antioxidant in the vehicle. This dispersion of isotretinoin in the vehicle is then micronized in accordance with the process of the invention. © 15 © In the stock dispersion, the concentration (w/w) of isotretinoin in the oily vehicle is 1-50%, preferably 10-40% and most preferably 20-35%. After micronization, the stock dispersion may then be combined with additional pharmaceutically acceptable ingredients to arrive at a final formulation for filling soft gelatin capsules. An example of a stock dispersion containing 20% isotretinoin is shown in

Table 1.

Table 1: Formulation of a 20% (w/w) isotretinoin stock dispersion

Butylated Hydroxyanisole (BHA) 0.0670

Soybean Oil 79.9330

The present invention is also directed to a composition in unit dosage form for enteral administration comprising the micronized isotretinoin composition of the } invention and a pharmaceutically acceptable carrier. The unit dosage form contains from about 1 mg to about 50 mg of isotretinoin, preferably from about 3 to about 25 mg of isotretinoin. The oily or other pharmaceutically acceptable vehicle may, itself, act as the pharmaceutically acceptable carrier without the addition of further excipients. The unit dosage form may be any conventional form of tablet, capsule, etc. known in the art, so long as the micronized isotretinoin composition of the invention may be incorporated therein. The preferred unit dosage form is a gelatin capsule, especially a soft gelatin capsule such as those produced by R.P. Scherer

North America, Inc. of Saint Petersburg, Florida. The preparation of a final formulation for filling soft gelatin capsules is described in Example 5.

Analysis of the particle size of the micronized isotretinoin is preferably based upon at least 3 samples which are taken randomly from different parts of the mixing container. Particle size analysis of the isotretinoin may be carried out using a conventional particle size analyzer (e.g., the Malvern MasterSizer' Model X

Version 2.5). The resultant micronized isotretinoin suspension should have a mean isotretinoin particle size of 5-30 um preferably of 5-20 um. Typical mean particle size data are presented in Table 2. .

Table 2: Representative particle size data for isotretinoin following homogenization and liquid jet micronization at 12,000 psi (data are after 2 passes, and average of 3 measurements)

After high shear 9.5+0.2 um 583102um [134.006 um ld

After liquid jet 3240.0 um 144403 um | 46.8+0.9 um micronization

It has been unexpectedly found that reducing the wax content of isotretinoin compositions having a mean particle size between 5 um and 30 um results in

@ i. WO 0025772 PCT/EP99/08208

CC 7 improved absorption of isotretinoin in the absence of food. While it is known that isotretinoin containing compositions having greater than twenty-two percent (22%) wax tend to diminish the bioavailabilty of the active ingredient, no studies

So on isotretinoin having a mean particle size between 5 um and 30 pm have addressed the effect of wax concentration on “food effect.”

Isotretinoin is a lipophilic substance. Accordingly, administration is typically effected in the presence of food to maximize absorption of isotretinoin into the blood. It is known that individuals who take isotretinoin (mean particle size between 90 pum and 100 pm) in the absence of food show a reduction in their isotretinoin blood level as compared with individuals who take isotretinoin in the presence of food.

To test the food effect on the bioavailability of isotretinoin having a mean particle size between 5 um and 30 um, the following experiments were performed. The : : "experiments demonstrate that for isotretinoin having a mean particle size between ; 5 wm and 30 um, the food effect diminishes as the concentration of wax is lowered.

This reduction in wax concentration correlates to a decrease in viscosity of the composition being tested. Amazingly, compositions having a wax content of about 18% (specifically 18.2%) were found to be markedly reduced food effect when compared to a composition containing 19.7% by weight of a wax mixture (disclosed in European Patent Publication No. 0 184 942, published August 8, 1990). It is believed that the reduced viscosity (185 to 600 centipoise) of isotretinoin containing compositions having between about 10% and about 18% wax will exhibit superior properties by minimizing food effect on isotretinoin bioavailablity.

Chemical assay of isotretinoin for different formulations investigated was carried out using a stability indicating method for isotretinoin where a high performance liquid chromatography procedure was used. The pump was Waters 600 E multisolvent delivery system with an autosampler of Waters WISP 717 plus, at a temperature of 5°C. The drug was tested at a wavelength of 353 nm using a

Thermoseparations Spectromonitor 3200 detector.

Example 1

Fluid energy milling : Fluid energy (jet) mill size reduction involves acceleration of particles so that grinding occurs by particle-to-particle impact or impact against a solid surface.

Fluid energy mills are used for micronization because of the high impact velocities possible as a result of particle acceleration in a fast gas stream. Particle velocities in a fluid energy mill are in the range of 300 to 500 meters per second, compared with 50 to 150 meters per second in a mechanical impact mill.

In a typical fluid energy mill process, powdered isotretinoin was fed into a mill (Jet-

O-Mizer™, Fluid Energy Aljet, Plumsteadville, Pennsylvania) using a vibratory feeder which controlled the feed rate of the powder. There were three main factors which controlled the size reduction process: the powder feed rate, air pressure on the pushing nozzle (25-35 psi for a lab scale mill), and air pressure on the grinding nozzle (40-50 psi for a lab scale mill). The milling process for isotretinoin was carried out using either nitrogen or air. Samples were selected from the micronized powder and tested for potency and particle size. Results are shown in Table 3.

Example 2

Homogenization

Particle size reduction of isotretinoin was achieved using a high shear homogenizer (Model CJ4C 16#, Arde-Barinco, New Jersey). Isotretinoin was added to soybean oil (Table 1 formulation with antioxidant) and homogenized at high speed for different times (30 minutes to 6 hrs). Samples (2 g) were taken at different mixing times and tested for particle size of isotretinoin using Malvern MasterSizer Model

X Version 2.5. Results are shown in Table 3. It was also found that reduction in particle size was a function of the mixing time.

Example 3

Wet milling

Particle size reduction of isotretinoin was achieved using a media milling machine (Dispermat SL, VMA-Getzmann GMBH, Germany) operated at 3000 RPM.

Isotretinoin was added to soybean oil (Table 1 formulation with and without antioxidant) and homogenized at high speed using a high shear homogenizer

: Wi rn WO 00125772 PCT/EP99/08208

WC 9 (Model CJ4C 16#, Arde-Barinco, New Jersey). The formed suspension was pumped through the grinding chamber of the media milling machine containing grinding glass beads. Particle size reduction occurs through both attrition and impact to ~ produce the suspension of micronized isotretinoin. Samples (2 g each) were tested for particle size using Malvern MasterSizer Model X Version 2.5. Results are shown - in Table 3.

Example 4

High shear homogenization and liquid jet micronization

Isotretinoin which was stored at -20 °C in a sealed container was brought to room temperature and was suspended in soybean oil (Table 1 formulation with and without antioxidant). The isotretinoin suspension was passed through a high shear homogenizer, as described in Example 2, until the isotretinoin particle size in the suspension was in the range of 50-65 pm. The suspension thus prepared was passed } through a MICROFLUIDIZER® M110F liquid jet micronizer (Microfluidics "International Corp., Newton, MA) at room temperature operated at 12,000 psi.

After 2 passes, the mean particle size of the isotretinoin in the suspension was 10-20 um. The isotretinoin particle size was determined using a Malvern MasterSizer

Model X Version 2.5. Results are shown in Table 3.

The following table compares the results for fluid energy mills with various embodiments of the invention.

ony [= vw R

REQ

~55 * 829 = Q nw EE 5 0 0 < oOo CS) on

I

[= 4 aR

SER

=~ 383 © EN 3 Q -— : wn ; ~ a 2 ES gS In 8 od

By <n fa) — on — 15

S oc c 2 £ 5

S N

IRE

— >. 8 © J ~~ § |g&88 - Is |o = —- ©) ame wn [=] [=] [=4 =

Fl c = ‘a 8 3 RE

T >= 0 = 32.9 no

ET [oS Nn wi c —_ .g E : r= = < om 2 lo [nn |e ~ = Id 0° |v ov |g |= IN =a) «tee on — — — < on [9] te v

E 2 ’ £ =

Cc t= £ a GS n « wn § < IS AS LO A TI IN ~ «oi = 4 _— \O 0 [aS I~ y— — ve I]

BH c

JZ =] = [=] e [=] 5 < 2 8 2 8 Ls] [hd — > sb Ld com

E < B18 3% |S%< |3_ |E - ot - Ad — 3 EE IF I |= IE § o SHI [EHS |8 — lo 2 58 |Z |5 |B |= wN< [N/E (NT

[3] be Sr ad [@] [o) QO = © = C =m io] o |2 g |= |= (& |£ AL [gas |EQ < "om = 2 bet - = = E EEx 6 = 0 gs == j= IY] <4 £ £ z z [=] SD .= Da = 25 XI

J Is o z Tos (Lox = 3 [=

S 2 BB (Bs | | |e w BP = 2 = |= =o 2 |= £ IE [E |S « Ee) 8 0 soT |[£ a=) |= hf [7] [7] = = [ [Y] ~~ rz FE ~ g ce |x Oo |& eg |= |= En [& MK [8 = tS » © |v v IS [3 [va (©wOCe [© O2 OS |= r= yg bs © © -— ££ = ££ == LL = = ££ =~ []

Ne Is [5 [8 |B [== 22S JERE Cp c = SEE BF EE T+2 8 +S |Z +E (3 & = 5 i 5 on Oc. [a9 2 |g 2 2 |2 - f= ml — ~ ~ i) *

8 Co WO 00125772 PCT/EP99/08208 ; of ee ay -11- + Examples :

Preparation of Final Capsules : : Table 4: Formulation of a final suspension for filling gelatin capsules " [Tsotretinoin Soft Gelatin Capsules Fill Composition (in mg per capsule) oo suspension

NE IL en mL

J. LA

LC LR NI

2 *** Final isotretinoin quantity per capsule , : p During the preparation of the final suspension, the vehicle (soybean oil) was : warmed to about 70°C while adding the remainder of BHA and mixed using a , suitable mixer until BHA was completely dissolved. Hydrogenated soybean oil flakes were added to the solution of BHA in soybean oil while mixing until it was uniformly incorporated. Subsequently, beeswax purified, hydrogenated vegetable oil and disodium edetate were added and mixing was continued to form a uniform suspension. The suspension was allowed to cool to 40° - 45°C before adding the 20% micronized isotretinoin stock dispersion, and mixing was continued until a homogeneous suspension was formed. The final suspension was blanketed with nitrogen for storage. The completed suspension was incorporated into soft gelatin capsules using conventional processing technology.

Example 6 ‘Preparation and testing of isotretinoin formulations of different wax concentrations

A thirty-five percent (35%) isotretinoin stock dispersion in soybean oil was prepared by warming the soybean oil to 70° + 5°C and then adding BHA using a propeller : mixer until the BHA was completely dissolved. The mixture was cooled to 40° - 45°C, before adding isotretinoin (under nitrogen) while mixing. The mixture was homogenized using a high shear mixer-homogenizer for 1 hour at high speed. The mixture was further passed through a wet milling machine similar to the one described in Example 3. The mean particle size ( 50" percentile) of isotretinoin was 20 um. The formulation composition of the thirty-five percent (35%) isotretinoin stock dispersion in soybean oil is shown in Table 5.

Table 5: Formulation composition of the 35% stock dispersion er | em 2 Butylated Hydroxyanisole 0.044 (BHA)

Soybean Oil 37.11

Using the thirty-five percent (35%) stock dispersion of isotretinoin. four (4) formulations (P1, P2, P4 and P5) were prepared with different wax concentrations (18.2%, 19.7%, 10%, and 15% (w/w), respectively]. The composition of each of the four formulations, P1, P2, P4, and P5, is shown in Tables 6,7,8 and 9, respectively.

if Cn WO 00/25772 PCT/EP99/08208

Loan a : 13. Co

Table 6: Formulation composition of P1 m=

I i

I hii : Table 7: Formulation composition of P2 1" | 35% Stock Dispersion IEE 57.150

El ——

I

ES

* Wax mixture: 1 Part: Yellow wax (beeswax purified) 4 parts: Hydrogenated vegetable oil 4 parts: Vegetable shortening (hydrogenated soybean oil flakes)

-14- oo

Table 8: Formulation composition of P4 } a I id ! 1 | 3% Stock Dispersion Stock Dispersion EES © 57.150

I a

I i al

Table 9: Formulation composition of P5

Nd I iid

Disodium Edetate en

For formulations P1, P4 and P5, during the preparation of the final suspension, the vehicle (soybean oil) was warmed to about 70°C while adding the remainder of BHA and mixed using a suitable mixer until BHA was completely dissolved.

og on WO 0025772 PCT/EP99/08208

Fo Hydrogenated soybean oil flakes was added to the solution of BHA in soybean oil oo while mixing until it was uniformly incorporated. Subsequently, beeswax purified, hydrogenated vegetable oil and disodium edetate were added. Mixing was continued to form a uniform suspension. The suspension was allowed to cool to 40° - 45°C before adding the 35% stock dispersion of isotretinoin, and mixing was continued until a homogeneous suspension was formed. The final suspension was blanketed with nitrogen for storage. The completed suspension was manually incorporated into hard gelatin capsules.

Formulation P2 (disclosed in European Patent Publication No. 0 184 942, published

August 8, 1990) was prepared in a manner similar to the other three (3) formulations. However a wax mixture (the composition of which is described with

Table 7) was prepared first before addition to the warmed soybean oil in accordance with the published European Patent Publication. After addition of the wax mixture, "the processing continued as for the other three (3) formulations, i.e. P1, P4, and PS.

The viscosity of all formulations was measured at 25°C using a Brookfield Digital

Viscometer Model DV-II equipped with Brookfield Small Sample Adapter Model } ~ SSA-15/7R using spindle # 15 set at 100 rpm Knob speed. Viscosity data for all four ) (4) formulations are shown on Table 10. : The four (4) formulations were orally administered to fed and fasted dogs to compare the effect on plasma exposure. Six (6) male and six (6) female dogs were placed into two (2) groups of three (3) males and three (3) females according to a standard randomization procedure. The 4 formulations (P1, P2, P4 and P5) were administered to each dog at 20 mg isotretinoin per dog under fed and fasted conditions. Blood samples were collected from all dogs into tubes containing potassium oxalate and sodium fluoride as anticoagulant, and placed over ice prior to centrifugation. Samples were taken prior to dosing and 1 hr, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, 24 hrs, 28 hrs and 32 hrs after dosing. Plasma was separated after cold centrifugation under yellow light, frozen in amber vials at a minimum of - 60°C and delivered for assay. A minimum of 1.0 mL of plasma was provided for assay. All pharmacokinetic parameters of isotretinoin were calculated by using

Watson (v 5.4.00.03) validated laboratory information system. The pharmacokinetic parameters were estimated from the individual data. The parameters reported are

IY ‘e f the maximum plasma concentration (Cmax), the time to reach the maximum plasma concentration (Tmax), and the area under the plasma concentration-time curve from zero to 32 hours (AUCy.3; hr). The observed Cpax and Trax were taken directly from the individual plasma concentration-time profiles. The AUCq.3; , was calculated using the linear trapezoidal rule. The mean pharmacokinetic data are shown in

Table 10.

4 « WO 006/25772 PCT/EP99/08208 (td Tew 2 ss « 8 HA

NR

Oo 2 8 nn on a) by) 0 =~ nn [69 — — — o — on [Va} hoa — =] — [Va [a] oN = +H +i + + o =)

S w |S Pe) D co un ~ [Ta] wn » < = ve) Nel ~ v= ~ o © 0 2 % ~ 18 |Z |a |’ 5 [7] [o) — [a ol +I +H oS a «x E | H [+H | o o : =e Lo) E eb Ie) on ~ — . =e I) c ~ oe) — — oS © to LO = a aA — ~~ ir BERERE ~~ 8.g = x Ive) a) wn = Eg i” © xR — . R= = la |# [HH | H y 4% of 18 1g |g |g gl 8 RE BERERVRE 4 ey < E = on < pv Y=}

SI's » 0 ol © id 0 © : gl | 8 ~ 12 5 IR ~~ . =p Qa =) + < + ~N [vl — o ~~ [=)} = wn = a = 3 ~ red gle |= |O 2 & | — ~ “ Yl <2 2 9 : [x] ~~

SE |’ og | 2 = ls 2 - = Q

[2] wn ~~ wn [Ya]

E 2 o ~ 0 — > fra — — on

SE

— 2 2 x

Ag

Ld c

[8] db =] 1) [&) . % ~N ~ S

Zz =) Io) =] nn — ey p— ay = 0 = < 5

E] g 2) o~ wn [24 [=P (=5 —

-18- CL

Upon reading this specification various alternative embodiments will become obvious to the skilled artisan. These variations are to be considered within the scope and spirit of the subject invention which is only to be limited by the claims that follow and their equivalents.

Claims

C vi / ip WO 0025772 PCT/EP99/08208 Claims

1. A process for the manufacture of a micronized isotretinoin composition, the composition comprising isotretinoin having a mean particle size in the range from : about 5 pm to about 30 um suspended in an oily or other pharmaceutically acceptable vehicle, wherein the process comprises: 1) dispersing isotretinoin having a mean article size greater than about 30 - p 8 g p g pm in the vehicle to form a suspension containing 1-50% by weight of isotretinoin; 2) subjecting the suspension to mechanical means which produce shear, impact, cavitation or attrition so as to reduce the mean particle size of the isotretinoin to a particle size in the range from about 5 pm to about 30 pm; whereby the micronized isotretinoin composition is produced. :

2. The process of claim 1, wherein the mechanical means is wet milling.

3. The process of claim 2, wherein the suspension contains from 10-40% by weight : 15 of isotretinoin.

4. The process of claim 3, wherein the suspension contains from 20-35% by weight of isotretinoin.

5. The process of claim 2, wherein the vehicle is an oily vehicle.

6. The process of claim 5, wherein the oily vehicle comprises soybean oil, peanut oil, olive oil, a mono-, di- or triglyceride of a C5-Cis fatty acid, C¢-Cis fatty acid, polyethylene glycol, a polyglycolized glyceride, glycerol, propylene glycol, a mono-, i di- or triester of propylene glycol, or a polyethylene glycol.

7. The process of claim 6, wherein the oily vehicle is soybean oil.

8. The process of claim 1, wherein the mechanical means is high shear ‘homogenization.

PCT/ER99/08208 \,. -20- Ce .

9. The process of claim 8, wherein the suspension contains from 10-40% by weight of isotretinoin.

10. The process of claim 9, wherein the suspension contains from 20-35% by weight of isotretinoin.

11. The process of claim 8, wherein the vehicle is an oily vehicle.

12. The process of claim 11, wherein the oily vehicle comprises soybean oil, peanut oil, olive oil, a mono-, di- or triglyceride of a Cs-C,3 fatty acid, polyethylene glycol, a polyglycolized glyceride, glycerol, propylene glycol, a mono-, di- or triester of propylene glycol, or a polyethylene glycol.

13. The process of claim 12, wherein the oily vehicle is soybean oil.

14. The process of claim 1, wherein the mechanical means is liquid jet micronization.

15. The process of claim 14, wherein the suspension contains from 10-40% by weight of isotretinoin.

16. The process of claim 15, wherein the suspension contains from 20-35% by ) weight of isotretinoin.

17. The process of claim 14, wherein the vehicle is an oily vehicle.

18. The process of claim 17, wherein the oily vehicle comprises soybean oil, peanut oil, olive oil, a mono-, di- or triglyceride of a Cs-Cj3 fatty acid, Cs-Cis fatty acid, polyethylene glycol, a polyglycolized glyceride, glycerol, propylene glycol, a mono-, di- or triester of propylene glycol, or a polyethylene glycol.

19. The process of claim 18, wherein the oily vehicle is soybean oil.

20. The process of claim 1, wherein the mechanical means is high shear homogenization followed by liquid jet micronization.

21. The process of claim 20, wherein the suspension contains from 10-40% by weight of isotretinoin.